CN102973745A - Traditional Chinese medicine composition for treating central retinitis and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating central retinitis and preparation method thereof Download PDFInfo
- Publication number
- CN102973745A CN102973745A CN201210545443XA CN201210545443A CN102973745A CN 102973745 A CN102973745 A CN 102973745A CN 201210545443X A CN201210545443X A CN 201210545443XA CN 201210545443 A CN201210545443 A CN 201210545443A CN 102973745 A CN102973745 A CN 102973745A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- restrains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating central retinitis, which is prepared from the following raw materials in parts by weight: 10-40 parts of phaseolus calcaratus, 1-16 parts of rhizoma alismatis, 5-25 parts of poria, 1-16 parts of radix stephaniae tetrandrae, 2-22 parts of radix astragali, 5-25 parts of radix salviae miltiorrhizae, 1-20 parts of Chinese angelica, 1-20 parts of rhizoma atractylodis macrocephalae, 5-25 parts of earthworm, 1-20 parts of herba epimedii, 1-20 parts of cassia twig, 8-28 parts of caulis spatholobi and 1-13 parts of liquorice root. The traditional Chinese medicine composition disclosed by the invention has moderate property and good curative effect, and is used for treating central retinitis without laser photocoagulation.
Description
Technical field
The present invention relates to a kind of Chinese medicine, relate in particular to a kind of Chinese medicine composition that is used for the treatment of central serous chorioretinopathy, also relate to the preparation method of this kind Chinese medicine composition.
Background technology
Central serous chorioretinopathy claims again central serous chorioretinopathy, is because the pigment epithelium barrier function is not normal, macula area neuroepithelium of retina serosity is stripped off caused retinopathy.Acute middle slurry, chronic middle slurry and bulla detachment of retina.
This disease is mainly in person between twenty and fifty, simple eye morbidity during morbidity, metamorphopsia, diminish, variable color, there are a circular Lycoperdon polymorphum Vitt or a brown color shadow, optical fundus foveal reflex disperse in the center at the moment.
Belong to this understanding of self-limited disease based on middle slurry, the middle slurry therapeutic strategy that a lot of ophthalmologists follow is to adopt conservative treatment.A kind of situation is not give any treatment, disease is taked the attitude of letting matters drift; Another situation is to give " placebo " treatments such as patient's vitamin C, vitamin B1, rutosids, bendazol, creatinine.As if because the self limiting of middle slurry, these treatments also can make the patient obtain satisfied " curative effect ".For expectant treatment, most of patients took a turn for the better after ill 4-6 month voluntarily, but still had 5% patient's protracted course of disease or aggravation to cause vision to be badly damaged.
In addition, the treatment means that middle slurry is relatively more commonly used is the laser photocoagulation treatment.Previously centering is starched pathogenetic understanding and is mainly derived from the FFA check result.Because checking, FFA can find clear and definite RPE breakthrough, so think that middle slurry primary affection is positioned at the RPE layer.But cause RPE barrier function damage and serosity RPE and (or) profound cause that breaks away from of neural retina and unclear.And the theoretical foundation of middle slurry laser photocoagulation treatment is to be based upon FFA to check on the RPE breakthrough basis of finding, is to solidify the RPE breakthrough by the heat effect of laser to reach therapeutic purposes thereby adopt the laser photocoagulation treatment.But clinical practice shows that the laser photocoagulation treatment can be sealed the RPE breakthrough, accelerates the absorption that serosity RPE breaks away from, and shortens the course of disease, is conducive to vision restoration; But long-term observation finds that the laser photocoagulation treatment shows can improve patient's late result or minimizing relapse rate.
Summary of the invention
Technical problem to be solved by this invention provides that a kind of property of medicine is gentle, good effect, without the Chinese medicine composition of laser photocoagulation therapeutic community property retinitis, also relate to the preparation method of this kind Chinese medicine composition.
For solving the problems of the technologies described above, be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, made by the crude drug of following weight portion:
1～13 part in 10～40 parts of Semen Phaseolis, 1～16 part of Rhizoma Alismatis, 5～25 parts of Poria, 1～16 part of Radix Stephaniae Tetrandrae, 2～22 parts of the Radixs Astragali, 5～25 parts of Radix Salviae Miltiorrhizaes, 1～20 part of Radix Angelicae Sinensis, 1～20 part of the Rhizoma Atractylodis Macrocephalae, 5～25 parts of Pheretimas, 1～20 part of Herba Epimedii, 1～20 part of Ramulus Cinnamomi, 8～28 parts of Caulis Spatholobis and Radix Glycyrrhizae.
As a kind of preferred technical scheme, be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, made by the crude drug of following weight portion:
3～5 parts in 15～35 parts of Semen Phaseolis, 5～10 parts of Rhizoma Alismatis, 10～20 parts of Poria, 5～10 parts of Radixs Stephaniae Tetrandrae, 8～15 parts of the Radixs Astragali, 12～20 parts of Radix Salviae Miltiorrhizaes, 5～15 parts of Radix Angelicae Sinensis, 5～15 parts of the Rhizoma Atractylodis Macrocephalaes, 10～20 parts of Pheretimas, 5～15 parts of Herba Epimedii, 5～15 parts of Ramulus Cinnamomi, 15～20 parts of Caulis Spatholobis and Radix Glycyrrhizae.
As a kind of technical scheme of the best, be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, made by the crude drug of following weight portion:
3 parts in 30 parts of Semen Phaseolis, 6 parts of Rhizoma Alismatis, 15 parts of Poria, 6 parts of Radixs Stephaniae Tetrandrae, 12 parts of the Radixs Astragali, 15 parts of Radix Salviae Miltiorrhizaes, 10 parts of Radix Angelicae Sinensis, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Pheretimas, 10 parts of Herba Epimedii, 10 parts of Ramulus Cinnamomi, 18 parts of Caulis Spatholobis and Radix Glycyrrhizae.
As another aspect of the present invention, a kind of preparation method that is used for the treatment of the Chinese medicine composition of central serous chorioretinopathy also is provided, may further comprise the steps:
(1) by proportioning the crude drug of weight portion is put in the marmite, then added water soaking 20～30 minutes;
(2) add again water and do not have described crude drug, decocted 40-50 minute, then medicinal liquid is poured out 150～200 milliliters;
(3) add again warm water 500-800 milliliter, decoct to get medicinal liquid.
Also provide another to be used for the treatment of the preparation method of the Chinese medicine composition of central serous chorioretinopathy, may further comprise the steps:
(1) by proportioning the crude drug of weight portion is put in the marmite, then added water soaking and obtained soaking medicine in 20～30 minutes;
(2) add again water and do not have 1-5 centimetre of described immersion medicine, decocted 45 minutes, then medicinal liquid is poured out 150～200 milliliters, obtain medicinal residues;
(3) the described medicinal residues with step (2) cool off, and then add cold water 500-800 milliliter, decoct to get medicinal liquid.
The present invention in use, the medicinal liquid that decoction can be obtained is drunk every day, take 10 days as a course for the treatment of.
In the various crude drug in Chinese medicine composition of the present invention, property of medicine pharmacology separately is as follows:
Semen Phaseoli: it is red to have another name called Hepar Sus domestica red (" herbal classic is met former "), Du's Semen Phaseoli (" book on Chinese herbal medicine is just read "), rice Semen Phaseoli, Mao Chaichi, rice.Meridian distribution of property and flavor: sweet acid, flat.Enter the heart, small intestine meridian.Effect: diuretic dehumidifying, and blood evacuation of pus, subduing swelling and detoxicating.
Rhizoma Alismatis: the dry tuber of plant Rhizoma Alismatis.Meridian distribution of property and flavor: sweet in the mouth; Light; Cold in nature.Return kidney; Urinary bladder channel.Effect: promoting diuresis to eliminate damp pathogen; It is treating stranguria to expel the heat-evil.Main dysuria; The puckery pain of pyretic stranguria; The edema distension; Have loose bowels; Dizziness due to fluid-retention; Seminal emission.
Poria: be commonly called as Song Ling, Poria, for colonizing in the fungi plant on the pinaster root, shape is as Rhizoma Dioscoreae esculentae, crust pitchy, the inside white or pink.Meridian distribution of property and flavor: sweet, light, flat.GUIXIN warp, lung meridian, spleen channel, kidney channel.Effect: diuretic medicine; Diuretics with the action of eliminating dampness.
Radix Stephaniae Tetrandrae: the dry root of menispermaceous plants Radix stephaniae tetrandrae or aristolochiaceae plant Radix Aristolochiae Fangchi.Meridian distribution of property and flavor: hardship, cold.Enter bladder, spleen, kidney channel.Effect: inducing diuresis to remove edema, wind-expelling pain-stopping.
The Radix Astragali: claim again Radix Astragali or northern Millefolium, also make Radix Astragali or Radix astragali, one of conventional Chinese medicine is the root of leguminous plant Radix Astagali or Radix Astragali.Meridian distribution of property and flavor: sweet, tepor.Return lung, spleen, liver, kidney channel.Effect: benefiting QI for strengthening the superficies, arresting sweating take off, hold in the palm the effect of skin ulcer granulation promoting, inducing diuresis to remove edema admittedly.
Radix Salviae Miltiorrhizae: have another name called Radix Salviae Miltiorrhizae, Radix Salviae Miltiorrhizae, Arisaema balansae Engl. etc.Be the dicotyledon Labiatae, dry root and rhizome.Meridian distribution of property and flavor: hardship is slightly cold.Enter the heart, Liver Channel.Effect: promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, the relieving restlessness that clears away heart-fire, nourishing blood to tranquillize the mind.
Radix Angelicae Sinensis: root can be used as medicine, and is one of the most frequently used Chinese medicine.Meridian distribution of property and flavor: warm in nature, sweet in the mouth, suffering.Return liver, the heart, spleen channel.Effect: enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.
The Rhizoma Atractylodis Macrocephalae: perennial herb, the nice and cool weather of happiness is used as medicine with rhizome.Meridian distribution of property and flavor: bitter, sweet, temperature.Return spleen, stomach warp.Effect: air making-up and spleen enlivening, dampness diuretic, hidroschesis, antiabortive.
Pheretima: be the dry body of Annelida hard iron earthworm section animal Pheretima aspergillum.Meridian distribution of property and flavor: cold in nature, salty in the mouth.Effect: collateral dredging, relieving asthma diuresis.
Herba Epimedii: have another name called Herba Epimedii, Herba Epimedii generally refers to the aerial parts of plant, and Herba Epimedii refers to the underground dry rhizome of plant.Meridian distribution of property and flavor: hot, sweet, temperature.Return liver, kidney channel.Effect: kidney-replenishing, bone and muscle strengthening, wind-damp dispelling.
Ramulus Cinnamomi: be the dry twig of Lauraceae aiphyllium plant Cortex Cinnamomi.Meridian distribution of property and flavor: suffering; Sweet; Warm in nature.Effect: diaphoresis expelling pathogenic factors from muscles, warming the meridian and promoting blood circulation, supporing yang activating QI, dispersing cold for relieving pain.
Caulis Spatholobi: the dry rattan of leguminous plant spatholobus suberectus.Meridian distribution of property and flavor: bitter, sweet, temperature.Return liver, kidney channel.Effect: enrich blood, invigorate blood circulation, collateral dredging.
Radix Glycyrrhizae: the dry root and rhizome of glycyrrhizic legume.Meridian distribution of property and flavor: sweet, flat.Enter spleen, stomach, lung meridian.Effect: QI invigorating invigorating middle warmer; Relieving spasm to stop pain; Nourishing the lung to arrest cough; Eliminating fire and detoxication; Coordinating the actions of various ingredients in a prescription.
Taboo matters: the careful usefulness of anemia of pregnant woman.
Owing to adopted technique scheme, the present invention to produce following beneficial effect:
The present invention enriches blood with Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae and Caulis Spatholobi and invigorates blood circulation, the collateral dredging regulating menstruation is purport, be aided with the Rhizoma Atractylodis Macrocephalae, Ramulus Cinnamomi, Herba Epimedii, start with from air making-up and spleen enlivening, kidney-replenishing, warming the meridian and promoting blood circulation, assistant is with Semen Phaseoli, Rhizoma Alismatis, Poria, Radix Stephaniae Tetrandrae, the Radix Astragali, Pheretima, Radix Glycyrrhizae realization QI invigorating invigorating middle warmer and blood evacuation of pus, subduing swelling and detoxicating, the effects such as inducing diuresis to remove edema, wind-expelling pain-stopping, the liver heat removing that makes eye bright.The present invention is according to Traditional Chinese medical theory, and reasonable compatibility brings out the best in each other, the effect that realize that QI invigorating is enriched blood, warming the meridian and promoting blood circulation and blood evacuation of pus, suppressing the hyperactive liver makes eye bright.Prescription compatibility science of the present invention meets materialism and the Theories thought of Chinese medicine, considers the paathogenic factor of central serous chorioretinopathy, gives full play to the effect of prescription medicine.Good effect, without recurrence, sequela is few, and vision can be recovered normal level.The property of medicine is gentle, has no side effect.And without the laser photocoagulation treatment, reduced the injury to eyes.
Following case is used for further specifying beneficial effect of the present invention:
Case 1
Zhang, the man, 34 years old, the slight visual deterioration of patient, diminished and accompanies colour vision to change at metamorphopsia; Center or paracentral scotoma; Contrast sensitivity reduces.
Take behind the Chinese medicine composition that is used for the treatment of central serous chorioretinopathy provided by the invention one the course for the treatment of produce effects, continue to take lasting effects, take again rehabilitation after four courses for the treatment of.
Case 2
Liu, the man, 35 years old, the slight visual deterioration of patient, diminished and accompanies colour vision to change at metamorphopsia; Center or paracentral scotoma.
Take behind the Chinese medicine composition that is used for the treatment of central serous chorioretinopathy provided by the invention one the course for the treatment of produce effects, continue to take lasting effects, take again rehabilitation after three courses for the treatment of.
Case 3
Liu, woman, 41 years old, the slight visual deterioration of patient, center or paracentral scotoma; Contrast sensitivity reduces.
Take behind the Chinese medicine composition that is used for the treatment of central serous chorioretinopathy provided by the invention one the course for the treatment of produce effects, continue to take lasting effects, take again rehabilitation after three courses for the treatment of.
Case 4
The Ji, the man, 39 years old, the slight visual deterioration of patient, diminished and accompanies colour vision to change at metamorphopsia; See light grey muddy in the serous detachment district.
Take the Chinese medicine composition that is used for the treatment of central serous chorioretinopathy provided by the invention latter two of produce effects course for the treatment of, continue to take lasting effects, take again rehabilitation after five courses for the treatment of.
The specific embodiment
Below in conjunction with embodiment, further set forth the present invention.
Embodiment one:
Difference weighting raw materials Semen Phaseoli 10 restrains, Rhizoma Alismatis 1 restrains, Poria 5 restrains, Radix Stephaniae Tetrandrae 1 restrains, the Radix Astragali 2 restrains, Radix Salviae Miltiorrhizae 5 restrains, Radix Angelicae Sinensis 1 restrains, the Rhizoma Atractylodis Macrocephalae 1 restrains, Pheretima 5 restrains, Herba Epimedii 1 restrains, Ramulus Cinnamomi 1 restrains, Caulis Spatholobi 8 restrains and Radix Glycyrrhizae 1 restrains.
(1) by proportioning crude drug is put in the marmite, then added water soaking 20 minutes;
(2) add again water and do not have described crude drug, decocted 40 minutes, then medicinal liquid is poured out 150 milliliters;
(3) add again 500 milliliters in warm water, decoct to get medicinal liquid.
Embodiment two:
Difference weighting raw materials Semen Phaseoli 15 restrains, Rhizoma Alismatis 5 restrains, Poria 10 restrains, Radix Stephaniae Tetrandrae 5 restrains, the Radix Astragali 8 restrains, Radix Salviae Miltiorrhizae 12 restrains, Radix Angelicae Sinensis 5 restrains, the Rhizoma Atractylodis Macrocephalae 5 restrains, Pheretima 10 restrains, Herba Epimedii 5 restrains, Ramulus Cinnamomi 5 restrains, Caulis Spatholobi 15 restrains and Radix Glycyrrhizae 3 restrains.
(1) by proportioning crude drug is put in the marmite, then added water soaking 25 minutes;
(2) add again water and do not have described crude drug, decocted 45 minutes, then medicinal liquid is poured out 180 milliliters;
(3) add again 600 milliliters in warm water, decoct to get medicinal liquid.
Embodiment three:
Difference weighting raw materials Semen Phaseoli 30 restrains, Rhizoma Alismatis 6 restrains, Poria 15 restrains, Radix Stephaniae Tetrandrae 6 restrains, the Radix Astragali 12 restrains, Radix Salviae Miltiorrhizae 15 restrains, Radix Angelicae Sinensis 10 restrains, the Rhizoma Atractylodis Macrocephalae 10 restrains, Pheretima 15 restrains, Herba Epimedii 10 restrains, Ramulus Cinnamomi 10 restrains, Caulis Spatholobi 18 restrains and Radix Glycyrrhizae 3 restrains.
(1) by proportioning crude drug is put in the marmite, then added water soaking 30 minutes;
(2) add again water and do not have described crude drug, decocted 50 minutes, then medicinal liquid is poured out 200 milliliters;
(3) add again 700 milliliters in warm water, decoct to get medicinal liquid.
Embodiment four:
Difference weighting raw materials Semen Phaseoli 35 restrains, Rhizoma Alismatis 10 restrains, Poria 20 restrains, Radix Stephaniae Tetrandrae 10 restrains, the Radix Astragali 15 restrains, Radix Salviae Miltiorrhizae 20 restrains, Radix Angelicae Sinensis 15 restrains, the Rhizoma Atractylodis Macrocephalae 15 restrains, Pheretima 20 restrains, Herba Epimedii 15 restrains, Ramulus Cinnamomi 15 restrains, Caulis Spatholobi 20 restrains and Radix Glycyrrhizae 5 restrains.
(1) by proportioning crude drug is put in the marmite, then added water soaking and obtained soaking medicine in 20 minutes;
(2) add again water and do not have 1 centimetre of described immersion medicine, decocted 45 minutes, then medicinal liquid is poured out 150 milliliters, obtain medicinal residues;
(3) the described medicinal residues with step (2) cool off, and then add 600 milliliters in cold water, decoct to get medicinal liquid.
Embodiment five:
Difference weighting raw materials Semen Phaseoli 40 restrains, Rhizoma Alismatis 16 restrains, Poria 25 restrains, Radix Stephaniae Tetrandrae 16 restrains, the Radix Astragali 22 restrains, Radix Salviae Miltiorrhizae 25 restrains, Radix Angelicae Sinensis 20 restrains, the Rhizoma Atractylodis Macrocephalae 20 restrains, Pheretima 25 restrains, Herba Epimedii 20 restrains, Ramulus Cinnamomi 20 restrains, Caulis Spatholobi 28 restrains and Radix Glycyrrhizae 13 restrains.
(1) by proportioning crude drug is put in the marmite, then added water soaking and obtained soaking medicine in 30 minutes;
(2) add again water and do not have 3 centimetres of described immersion medicines, decocted 45 minutes, then medicinal liquid is poured out 200 milliliters, obtain medicinal residues;
(3) the described medicinal residues with step (2) cool off, and then add 700 milliliters in cold water, decoct to get medicinal liquid.
All from the present invention is to devise, the crude drug weight ratio adjustment of having done without creative work all drops within protection scope of the present invention.
Claims (5)
1. be used for the treatment of the Chinese medicine composition of central serous chorioretinopathy, it is characterized in that, made by the crude drug of following weight portion:
1～13 part in 10～40 parts of Semen Phaseolis, 1～16 part of Rhizoma Alismatis, 5～25 parts of Poria, 1～16 part of Radix Stephaniae Tetrandrae, 2～22 parts of the Radixs Astragali, 5～25 parts of Radix Salviae Miltiorrhizaes, 1～20 part of Radix Angelicae Sinensis, 1～20 part of the Rhizoma Atractylodis Macrocephalae, 5～25 parts of Pheretimas, 1～20 part of Herba Epimedii, 1～20 part of Ramulus Cinnamomi, 8～28 parts of Caulis Spatholobis and Radix Glycyrrhizae.
2. the Chinese medicine composition that is used for the treatment of central serous chorioretinopathy as claimed in claim 1 is characterized in that, is made by the crude drug of following weight portion:
3～5 parts in 15～35 parts of Semen Phaseolis, 5～10 parts of Rhizoma Alismatis, 10～20 parts of Poria, 5～10 parts of Radixs Stephaniae Tetrandrae, 8～15 parts of the Radixs Astragali, 12～20 parts of Radix Salviae Miltiorrhizaes, 5～15 parts of Radix Angelicae Sinensis, 5～15 parts of the Rhizoma Atractylodis Macrocephalaes, 10～20 parts of Pheretimas, 5～15 parts of Herba Epimedii, 5～15 parts of Ramulus Cinnamomi, 15～20 parts of Caulis Spatholobis and Radix Glycyrrhizae.
3. the Chinese medicine composition that is used for the treatment of central serous chorioretinopathy as claimed in claim 1 is characterized in that, is made by the crude drug of following weight portion:
3 parts in 30 parts of Semen Phaseolis, 6 parts of Rhizoma Alismatis, 15 parts of Poria, 6 parts of Radixs Stephaniae Tetrandrae, 12 parts of the Radixs Astragali, 15 parts of Radix Salviae Miltiorrhizaes, 10 parts of Radix Angelicae Sinensis, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Pheretimas, 10 parts of Herba Epimedii, 10 parts of Ramulus Cinnamomi, 18 parts of Caulis Spatholobis and Radix Glycyrrhizae.
4. be used for the treatment of the preparation method of the Chinese medicine composition of central serous chorioretinopathy such as described each of claim 1-3, it is characterized in that, may further comprise the steps:
(1) by proportioning the crude drug of weight portion is put in the marmite, then added water soaking 20～30 minutes;
(2) add again water and do not have described crude drug, decocted 40-50 minute, then medicinal liquid is poured out 150～200 milliliters;
(3) add again warm water 500-800 milliliter, decoct to get medicinal liquid.
5. be used for the treatment of the preparation method of the Chinese medicine composition of central serous chorioretinopathy such as described each of claim 1-3, it is characterized in that, may further comprise the steps:
(1) by proportioning the crude drug of weight portion is put in the marmite, then added water soaking and obtained soaking medicine in 20～30 minutes;
(2) add again water and do not have 1-5 centimetre of described immersion medicine, decocted 45 minutes, then medicinal liquid is poured out 150～200 milliliters, obtain medicinal residues;
(3) the described medicinal residues with step (2) cool off, and then add cold water 500-800 milliliter, decoct to get medicinal liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210545443XA CN102973745A (en) | 2012-11-30 | 2012-11-30 | Traditional Chinese medicine composition for treating central retinitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210545443XA CN102973745A (en) | 2012-11-30 | 2012-11-30 | Traditional Chinese medicine composition for treating central retinitis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102973745A true CN102973745A (en) | 2013-03-20 |
Family
ID=47848280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210545443XA Pending CN102973745A (en) | 2012-11-30 | 2012-11-30 | Traditional Chinese medicine composition for treating central retinitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102973745A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104189299A (en) * | 2014-09-19 | 2014-12-10 | 杜敏 | Traditional Chinese medicine preparation for treating central retinitis |
| CN105267466A (en) * | 2015-10-30 | 2016-01-27 | 方心淳 | Traditional Chinese medicine composition for treating retinitis |
| CN105362524A (en) * | 2015-12-14 | 2016-03-02 | 青岛华仁太医药业有限公司 | Traditional Chinese medicine composition for treating retinitis and preparation method of traditional Chinese medicine composition |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167966A (en) * | 2007-10-25 | 2008-04-30 | 寇连翠 | Traditional Chinese medicine formula for treating acute central retinitis |
| US20080317890A1 (en) * | 2007-06-21 | 2008-12-25 | Claude Jarakae Jensen | Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical |
| CN101332238A (en) * | 2008-08-04 | 2008-12-31 | 陈瑞萍 | Traditional Chinese medicine for treating vascular headache |
| KR20090031119A (en) * | 2007-09-21 | 2009-03-25 | 주식회사 국순당 | Anti-angiogenic composition comprising rhizopus sp |
| CN101683417A (en) * | 2008-09-23 | 2010-03-31 | 天津市中宝制药有限公司 | Traditional Chinese medicine composition with function of warming yang and gore removing |
| US20110045035A1 (en) * | 2008-04-29 | 2011-02-24 | Nikken Sohonsha Corporation | Methods of treating ophthalmic disorders |
| CN102210792A (en) * | 2011-05-10 | 2011-10-12 | 于晓峰 | Traditional Chinese medicine for preventing and treating deep venous thrombosis |
| KR101181216B1 (en) * | 2009-07-29 | 2012-09-07 | 한국생명공학연구원 | Pharmaceutical composition comprising extract or fraction from Evodia fructus or quinolone alkaloid compounds |
| CN102743532A (en) * | 2011-04-22 | 2012-10-24 | 王贵雪 | Chinese medicine for preventing and treating cerebral infarction |
| WO2012157790A1 (en) * | 2011-05-13 | 2012-11-22 | (주)아모레퍼시픽 | Composition containing ginseng berry extract for activating mitochondria |
-
2012
- 2012-11-30 CN CN201210545443XA patent/CN102973745A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080317890A1 (en) * | 2007-06-21 | 2008-12-25 | Claude Jarakae Jensen | Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical |
| KR20090031119A (en) * | 2007-09-21 | 2009-03-25 | 주식회사 국순당 | Anti-angiogenic composition comprising rhizopus sp |
| CN101167966A (en) * | 2007-10-25 | 2008-04-30 | 寇连翠 | Traditional Chinese medicine formula for treating acute central retinitis |
| US20110045035A1 (en) * | 2008-04-29 | 2011-02-24 | Nikken Sohonsha Corporation | Methods of treating ophthalmic disorders |
| CN101332238A (en) * | 2008-08-04 | 2008-12-31 | 陈瑞萍 | Traditional Chinese medicine for treating vascular headache |
| CN101683417A (en) * | 2008-09-23 | 2010-03-31 | 天津市中宝制药有限公司 | Traditional Chinese medicine composition with function of warming yang and gore removing |
| KR101181216B1 (en) * | 2009-07-29 | 2012-09-07 | 한국생명공학연구원 | Pharmaceutical composition comprising extract or fraction from Evodia fructus or quinolone alkaloid compounds |
| CN102743532A (en) * | 2011-04-22 | 2012-10-24 | 王贵雪 | Chinese medicine for preventing and treating cerebral infarction |
| CN102210792A (en) * | 2011-05-10 | 2011-10-12 | 于晓峰 | Traditional Chinese medicine for preventing and treating deep venous thrombosis |
| WO2012157790A1 (en) * | 2011-05-13 | 2012-11-22 | (주)아모레퍼시픽 | Composition containing ginseng berry extract for activating mitochondria |
Non-Patent Citations (1)
| Title |
|---|
| 李文亮等: "《千家妙方 下册》", 31 December 1982, article "中心性视网膜炎" * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104189299A (en) * | 2014-09-19 | 2014-12-10 | 杜敏 | Traditional Chinese medicine preparation for treating central retinitis |
| CN104189299B (en) * | 2014-09-19 | 2018-09-21 | 嘉兴日昌汽车配件有限公司 | A kind of Chinese medicine preparation of therapeutic community's property retinitis |
| CN105267466A (en) * | 2015-10-30 | 2016-01-27 | 方心淳 | Traditional Chinese medicine composition for treating retinitis |
| CN105362524A (en) * | 2015-12-14 | 2016-03-02 | 青岛华仁太医药业有限公司 | Traditional Chinese medicine composition for treating retinitis and preparation method of traditional Chinese medicine composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103028090B (en) | Traditional Chinese medicine composition for treating Qi deficiency | |
| CN104043087A (en) | Traditional Chinese medicine composition for treating Raynaud syndrome | |
| CN102973745A (en) | Traditional Chinese medicine composition for treating central retinitis and preparation method thereof | |
| CN101428114B (en) | Medicament for treating chronic hepatitis B, cirrhosis and liver ascites | |
| CN105012833A (en) | Traditional Chinese medicine for treating polyneuropathy | |
| CN103083616B (en) | Traditional Chinese medicine for treating ovarian cyst | |
| CN105012571A (en) | Drug for treating demyelinating polyneuropathy and preparation method of drug | |
| CN103816485A (en) | Traditional Chinese medicine composition for treating scleredema neonatorum and preparation method of traditional Chinese medicine composition | |
| CN104758845A (en) | External traditional Chinese medicine ointment for treating scapulohumeral periarthritis | |
| CN106361918A (en) | Traditional Chinese medicine patch for treating deficiency of kidney-yang | |
| CN105435055A (en) | Traditional Chinese medicine for efficiently treating polyneuropathy | |
| CN102940770B (en) | Traditional Chinese medicine for treating acute inflammatory demyelinating polyneuropathy | |
| CN105168572A (en) | Medicine for fast treating inflammatory demyelinating polyneuropathy | |
| CN104013765A (en) | Traditional Chinese medicine composition for treating deficiency of liver-yin and kidney-yin | |
| CN104042839A (en) | Traditional Chinese medicine composition for treating tinea versicolor | |
| CN103784621A (en) | Traditional Chinese medicine for treating scapulohumeral periarthritis and preparation method thereof | |
| CN103830513A (en) | Traditional Chinese medicine preparation for treating primary glaucoma | |
| CN105999087A (en) | Medicinal liquid for acupuncture and moxibustion for treating intrauterine adhesion and preparation method thereof | |
| CN101147763A (en) | Orally-administered medicine for treating chloasma | |
| CN105663992A (en) | Traditional Chinese medicine composition for treating chronic annexitis | |
| CN105250864A (en) | Traditional Chinese medicine for treating visceral dysfunction | |
| CN104784649A (en) | Traditional Chinese medicine decoction for treating scapulohumeral periarthritis | |
| CN104257773B (en) | A kind of oral drugs treating ankylosing spondylitis | |
| CN104042730A (en) | Traditional Chinese medicine preparation for treating chronic hepatitis | |
| CN100435841C (en) | Medicament for treating phlebitis of mammary gland |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130320 |